

# The extent of pain is associated with signs of central sensitization in patients with hip osteoarthritis

Willett, Matthew J; Siebertz, Mathias; Petzke, Frank; Erlenwein, Joachim; Rushton, Alison; Soldini, Emiliano; Barbero, Marco; Falla, Deborah

DOI:

[10.1111/papr.12851](https://doi.org/10.1111/papr.12851)

License:

Other (please specify with Rights Statement)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Willett, MJ, Siebertz, M, Petzke, F, Erlenwein, J, Rushton, A, Soldini, E, Barbero, M & Falla, D 2019, 'The extent of pain is associated with signs of central sensitization in patients with hip osteoarthritis', *Pain Practice*, pp. 1-12. <https://doi.org/10.1111/papr.12851>

[Link to publication on Research at Birmingham portal](#)

## **Publisher Rights Statement:**

This is the peer reviewed version of the following article: Willett, M.J., Siebertz, M., Petzke, F., Erlenwein, J., Rushton, A., Soldini, E., Barbero, M. and Falla, D. (2019), The Extent of Pain Is Associated With Signs of Central Sensitization in Patients With Hip Osteoarthritis. *Pain Pract.*, which has been published in final form at <https://doi.org/10.1111/papr.12851>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

## **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

# **THE EXTENT OF PAIN IS ASSOCIATED WITH SIGNS OF CENTRAL SENSITIZATION IN PATIENTS WITH HIP OSTEOARTHRITIS**

Matthew J Willett, MSc<sup>1</sup>, Dr Mathias Siebertz, MD<sup>2</sup>, Professor Frank Petzke, MD<sup>2</sup>, Dr Joachim Erlenwein, MD<sup>2</sup>, Dr Alison Rushton, EdD<sup>1</sup>, Emiliano Soldini, MSc<sup>3</sup>, Dr Marco Barbero, PhD<sup>4</sup>, Professor Deborah Falla, PhD<sup>1</sup>

1) Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham B15 2TT, UK

2) Center for Anesthesiology, Emergency and Intensive Care Medicine, University Hospital Göttingen, Germany

3) Research Methodology Competence Centre, Department of Business, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland (SUPSI), Manno, Switzerland

4) Department of Business, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland (SUPSI), Manno, Switzerland

Key words: Pain drawings, pain extent, central sensitization, hip osteoarthritis

Address correspondence and reprint requests to: Professor Deborah Falla, School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham B15 2TT, UK.

Email: d.falla@bham.ac.uk

28 ABSTRACT

29 Background: Central sensitization may be present in some patients with hip osteoarthritis (OA),  
30 often reflected as widespread pain. We examine the association between pain extent with signs  
31 of central sensitization and other clinical and psychological features in patients with hip OA.

32 Methods: Thirty patients with hip OA were recruited for this cross-sectional observational study.  
33 Participants completed pain drawings on a digital tablet, which displayed frontal and dorsal  
34 views of the body. The pain extent (%) for each participant was determined by combining the  
35 frontal and dorsal pixels shaded and dividing by the total pixels of the body chart area.

36 Participants completed patient reported outcome measures to assess for signs and symptoms of  
37 central sensitization and psychosocial factors. Quantitative sensory testing including pain  
38 pressure thresholds (PPTs) and Thermal Pressure Thresholds (TPTs) was performed at points  
39 anatomically local and distant from the hip.

40 Results: Women had significantly greater pain extent (6.71%) than men (2.65%) ( $z = -2.76$ ,  $p$   
41  $< 0.01$ ). Across all participants, increased pain extent was significantly associated with higher  
42 scores on the Widespread Pain Index ( $r_2 = 0.426$ ,  $p < 0.05$ ), Pain Detect ( $r_2 = 0.394$ ,  $p < 0.05$ ) and  
43 Pain Catastrophising Scale ( $r_2 = 0.413$ ,  $p < 0.05$ ), and with lower PPTs at the thenar eminence ( $r_2 = -$   
44  $0.410$ ,  $p < 0.05$ ), vastus lateralis ( $r_2 = -0.530$ ,  $p < 0.01$ ), vastus medialis ( $r_2 = 0.363$ ,  $p < 0.05$ ) and  
45 greater trochanter ( $r_2 = -0.373$ ,  $p < 0.05$ ).

46 Conclusions: Greater pain extent was associated with several measures of signs and symptoms of  
47 central sensitization in patients with hip OA. These results support the utility of the pain drawing  
48 for identifying signs of central sensitization in patients with hip OA.

49

50

## 51 INTRODUCTION

52 Osteoarthritis (OA) is the largest cause of individual level disability and costs for  
53 healthcare systems worldwide.<sup>1</sup> With populations living longer, healthcare costs related to OA  
54 are likely to escalate further.<sup>2</sup> The hip is the second most common site for OA after the knee<sup>3,4</sup>  
55 with a lifetime prevalence of approximately 25% in adults.<sup>5</sup> The prevalence of hip OA increases  
56 with age with women generally more likely to have painful hip OA and to seek treatment than  
57 men.<sup>4</sup> In addition to pain, patients with hip OA complain of physical symptoms including  
58 stiffness and muscle weakness<sup>3</sup>, and may present with psychological features including anxiety  
59 and low mood, which negatively affect quality of life.<sup>6</sup> Early diagnosis of OA is critical to  
60 successful management. Diagnosis of OA can however be challenging as symptoms do not  
61 always correlate well with the degree of articular damage present on imaging.<sup>7</sup> There is  
62 increasing evidence that central sensitization may be present in a sub-group of patients with hip  
63 OA,<sup>8-10</sup>.

64 Central sensitization involves several complex neurological reactions ultimately leading  
65 to an increased responsiveness of the neurons within the central nervous system to painful  
66 stimuli.<sup>11</sup> Patients who present with central sensitization as their dominant pain mechanism likely  
67 require specific/tailored treatment strategies to improve clinical outcomes.<sup>8</sup> Features of central  
68 sensitization include symptoms of high severity and irritability,<sup>12</sup> including an increased  
69 sensitivity to painful stimuli (hyperalgesia),<sup>13,14</sup> and the maintenance of symptoms in the absence  
70 of associated physical damage.<sup>15</sup> A further feature of central sensitization is widespread pain,  
71 which is pain experienced beyond the expected anatomical distribution of the pathology.<sup>16</sup>  
72 Widespread pain has been identified as a common symptom in patients with hip OA<sup>10,17,18</sup>. And

73 enlarged pain extent has been associated with magnified pain levels<sup>19-21</sup> and psychological  
74 distress<sup>21</sup> in patients with knee OA .

75 Pain drawings offer a practical way of quantifying pain extent and have been used to  
76 quantify the distribution of pain in patients with hip<sup>22</sup> and knee<sup>23</sup> OA, greater trochanteric pain  
77 syndrome,<sup>24</sup> low back pain,<sup>25</sup> fibromyalgia,<sup>26</sup> carpal tunnel syndrome,<sup>27</sup> chronic spinal pain,<sup>28</sup>  
78 whiplash associated disorder,<sup>29</sup> migraine,<sup>30</sup> and tension type headaches.<sup>31</sup> To date, only one study  
79 has examined the association between pain extent and clinical features of central sensitization in  
80 patients with OA.<sup>23</sup> Lluch Girebres et al.,<sup>23</sup> found that pain extent was greater in women, and  
81 associated with increased local pain severity and stiffness and reduced local and distant pain  
82 pressure thresholds in patients with knee OA. The authors suggested that pain drawings could be  
83 used easily in the clinic and recommended that further research was needed to better understand  
84 the association between greater pain extent and other clinical features in patients with OA.<sup>23</sup>

85 Although pain drawings have been used in patients with hip pain,<sup>17,18,22,32,33</sup> these studies  
86 have used pain drawings to describe but not quantify the distribution of symptoms. The most  
87 common pain distributions found in patients with hip OA were the groin, gluteal area, and  
88 anterior thigh,<sup>17,18,22,32,33</sup> with the greater trochanter also documented as an important site of  
89 symptoms.<sup>18,22</sup> Interestingly, larger pain areas were noted in approximately half of patients with  
90 hip OA who were either awaiting arthroplasty,<sup>17</sup> or had dysplasia.<sup>18</sup>

91 In this study we use a contemporary method to quantify the location and extent of pain in  
92 people with hip OA from a digital pain drawing and evaluate the association between pain extent  
93 and both clinical and psychological features. Specifically, we aimed to investigate whether an  
94 association exists between pain extent and perceived symptom severity, disability, and  
95 psychological features (through patient reported outcome measures) and physical measures of

96 pain perception (through quantitative sensory testing) in people with hip OA. Additionally, we  
97 evaluated whether differences in pain extent exists between men and women with hip OA.

## 98 METHODS

### 99 *Study Design and setting*

100 This cross-sectional observational study was conducted in the Pain Clinic of the  
101 Department of Anesthesiology, University Medical Center Gottingen, in the Georg-August-  
102 University of Gottingen in Germany, and is reported in line with the Strengthening the Reporting  
103 of Observational Studies in Epidemiology statement (STROBE).<sup>34</sup> The study was approved by  
104 the University Medical Center Gottingen ethics committee (reference number 27815) and was  
105 conducted according to the Declaration of Helsinki.

### 106 *Participants*

107 A convenience sample of thirty participants with hip OA were recruited via flyers placed  
108 in the University Hospital Gottingen Orthopedic Department, local orthopedic and physiotherapy  
109 practices, and by advertisements taken out in local newspapers. Based on the primary study aim  
110 of investigating associations between pain extent and signs and symptoms of central  
111 sensitization, a power level of 95% ( $\beta$ ), an alpha level of 0.05 ( $\alpha$ ) and a significant ‘moderate’  
112 correlation ( $r = 0.6$ ), a minimum sample of 25 participants was originally targeted. Participants  
113 were aged between 40-70 years, with a primary diagnosis of hip OA based on the International  
114 Classification of Diseases (ICD). Participants were excluded if they had other painful conditions  
115 (e.g. chronic cervical or lumbar pain, fibromyalgia, or rheumatic conditions). co-morbidities,  
116 such as severe cardiovascular, cognitive or neurological dysfunctions, or if their body-mass  
117 index (BMI) was  $>32$ . Those who were ingesting centrally acting analgesics were excluded,

118 while those taking non-opioid medication in moderate doses, or as needed, were included.  
119 Participants were requested to not take any non-opioid medications on the day of testing and  
120 were required to be able to give informed written consent to participate.

### 121 *Digital pain drawings*

122 Participants used a stylus pen (CS100B, Wacom, Vancouver, WA, USA) to define areas  
123 of pain on a digital tablet (iPad 2, Apple Computer, Cupertino, CA, USA) using a commercially  
124 available sketching software (SketchBook Pro) as previously described.<sup>28</sup> Different body charts  
125 showing either a male or female body chart with different views (frontal, dorsal) were selected  
126 and opened in the sketching software. The type, size, and color of the pen stroke were  
127 standardized for all participants. One researcher (MS) instructed the participants on the use of the  
128 digital tablet to complete the pain drawing and gave a brief demonstration and training to aid  
129 familiarization. The researcher emphasized the importance of comprehensively shading all  
130 painful areas, irrespective of their intensity or type.<sup>23</sup> The pain drawing was presented to the  
131 participant and the researcher used the standardized instruction ‘Please draw where you felt your  
132 usual pain during the last week on this body chart and try to be as precise as possible’.<sup>23</sup> Once the  
133 participant had completed the drawing, the researcher asked the participant to confirm that the  
134 pain drawing fully corresponded to their pain distribution, and the participants were given an  
135 opportunity to edit the drawing prior to being saved.<sup>23</sup> This method has shown good test-retest  
136 reliability within lumbar (intraclass correlation coefficients (ICC = 0.97) and cervical (ICC =  
137 0.92) pain populations previously.<sup>28</sup>

138 Pain extent expressed as the combined number of pixels coloured inside the frontal and  
139 dorsal body charts (the total area of pain for each participant) was measured using custom  
140 software for the analysis of pain drawings which was developed in Matlab®.<sup>26,28,29,35</sup> Pain

141 frequency and pain location maps were also computed as previously described<sup>26,28,29,35</sup>. The pain  
142 frequency map is a function in which all the pain drawings are overlaid and analyzed  
143 simultaneously to indicate the most frequently reported location of pain across all included  
144 participants. Pain location was determined by dividing the body charts into 45 anatomical  
145 regions (22 frontal and 23 dorsal). The number of participants who reported pain in each region  
146 was illustrated using coloured Histograms.<sup>28</sup> Pain extent, frequency, and location were computed  
147 for women and men separately.

#### 148 *Patient Reported Outcome Measures*

149 All participants were asked to complete the German version of several patient reported  
150 outcome measures including:

151 Measures of signs and symptoms of central sensitization and neuropathic pain:

- 152 • Fibromyalgia Survey Questionnaire (FSQ): A validated measure  
153 which evaluates physical and emotional distress based on the preliminary  
154 American College of Rheumatology (ACR) criteria, indicating a survey based  
155 diagnosis of fibromyalgia to be made through patient self-report which, however,  
156 may differ from the clinical diagnosis.<sup>36</sup> The FSQ combines the symptom  
157 severity score (SSS) with the widespread pain index (WPI). The SSS evaluates  
158 symptoms relating to sleep, fatigue, troubled thoughts and any additional  
159 symptoms on a 0-3 scale (0=not present to 3=extreme), with a score ranging from  
160 0 to 12. Patients were also asked if they experienced headaches, depression, or  
161 pain in lower abdomen, which were coded to be present (1) or not present (0). The  
162 WPI includes 19 non-articular pain sites, with each site being rated as 1 point.



163 Patients who score  $\geq 7/19$  on the WPI and  $\geq 5/12$  on the SSS or 3-6/19 on the WPI  
164 and  $\geq 9/12$  on the SSS are considered to have a diagnosis of fibromyalgia  
165 according to the Fibromyalgia Survey Diagnostic Criteria (FSDC).<sup>37</sup>

166 • PainDETECT (PD-Q): A validated measure that can be used as a  
167 screening tool for neuropathic pain,<sup>38</sup> the PD-Q evaluates pain intensity,  
168 characteristics, pattern and distribution to give a combined score out of 38, with a  
169 higher score being related to increased pain. A total score of  $\geq 19$  is indicative of  
170 neuropathic involvement with a 90% probability.<sup>38</sup> For the purpose of this study,  
171 only the descriptive items were analyzed, indicating the level of neuropathic pain  
172 like characteristics.<sup>39</sup>

173

174 Hip Symptoms:

175 • Oxford Hip Score (OSH-D): A 12-item measure which assesses  
176 stiffness, pain and physical disability in patients with hip OA with the German  
177 version demonstrating reliability and validity. Each item has 5 possible responses  
178 (scored 1-5), giving a maximum score of 60, with higher scores indicating  
179 increased difficulties with activities of daily living.<sup>40</sup>

180 • The Von Korff Scale (VKS): A measure of chronic pain<sup>41</sup> which  
181 grades pain intensity and disability and its German version has shown to be  
182 reliable and valid. The tool incorporates 6 items detailing pain intensity and  
183 impairment which are measured on 11-point numerical scales (0-10) and the  
184 number of disability days.<sup>42</sup> Patients are then 'graded' as chronic pain grade I

185 (low disability, low pain intensity), II (low disability, high pain intensity), III  
186 (high disability, moderately limiting) or IV (high disability, severely limiting).<sup>41,42</sup>

187 • Visual Analogue Scale (VAS): A widely used measure that  
188 evaluates pain intensity<sup>43</sup> that has demonstrated reliability and validity for patients  
189 with OA.<sup>44</sup> The VAS uses a 10cm line with ‘no pain’ and ‘worst possible pain’  
190 located at each end and participants were asked to indicate their average pain over  
191 the past four weeks by applying a vertical mark on the line.<sup>43</sup>

192

193 Psychosocial symptoms:

194 • Pain Catastrophizing Scale (PCS): A measure that evaluates pain  
195 catastrophizing, an important maladaptive psychological mechanism.<sup>45</sup> The  
196 German version has been validated on patients with chronic pain<sup>45</sup> and has been  
197 used extensively to assess knee OA populations.<sup>46,47</sup> The PCS has 13 items which  
198 are rated on a 5 point scale (scored 0-4) for a total score up to 52 points with  
199 higher scores equating to increased catastrophizing.<sup>46</sup>

200 • Tampa Scale for Kinesiophobia (TSK): A tool to evaluate fear of  
201 movement or re-injury in patients that has been validated and demonstrated  
202 reliability in German.<sup>48</sup> The TSK is a 17 item self-rated measure which uses a 4-  
203 point likert scale (1: ‘Strongly disagree; 4: Strongly agree) with higher scores  
204 indicating increased apprehension.<sup>49,50</sup>

205 • Chronic Pain Acceptance Questionnaire (CPAQ): A valid and  
206 reliable tool<sup>51</sup> which is the most commonly used self-report method to quantify  
207 pain acceptance in chronic pain populations.<sup>23</sup> The CPAQ incorporates two

208 factors: activity engagement and pain willingness, measured on a 7 point scale,  
209 from 0 (never true) to 6 (always) across 20 items, with higher scores indicating  
210 higher acceptance of chronic pain (Range 0-120).<sup>52</sup>

211 • Depression, Anxiety, Stress 21 Scale (DASS): A valid<sup>53</sup> and  
212 reliable<sup>54</sup> self-report measure to detect psychological factors affecting patients  
213 pain experience.<sup>54</sup> The tool consists of the 21 questions (7 each for depression,  
214 anxiety and stress respectively) which are scored on 4-point ordinal scales from 0  
215 ‘did not apply to me at all’ to 3 ‘applied very much to me most of the time’. A  
216 total score for each domain can be calculated by summing ordinal values and  
217 multiplying by 2 and each domain graded as normal, mild, moderate, severe or  
218 extremely severe.<sup>53</sup>

219

### 220 *Quantitative Sensory Testing*

221 One investigator (MS) conducted Quantitative Sensory Tests on all participants adapting  
222 a standardized protocol from the German Research Network on Neuropathic pain (DFNS).<sup>55</sup> All  
223 participants were instructed by the investigator using standardized instructions<sup>55</sup> and were  
224 familiarized with the testing procedures on neutral body sites. Testing was performed ipsilateral  
225 to the side of the painful hip with a mean of three scores taken as the final score for each  
226 reading.<sup>55</sup> A 30 second rest period was provided between repetitions.<sup>56,57</sup>

227 Pain Pressure Thresholds: Pain pressure thresholds (PPTs) were measured using a digital  
228 pressure algometer (Somedic Production, Stockholm, Sweden, Probe tip 1cm<sup>2</sup>) with pressure  
229 stimulation increasing at 50 kPa/s. PPTs were assessed at the greater trochanter (5cm distal and  
230 2cm anterior to Greater trochanter)<sup>9</sup>, gluteus medius muscle (3cm distally from the Iliac crest of

231 the proximal part of the muscle belly),<sup>58</sup> vastus medialis (3cm medial to the central point on  
232 medial aspect of patella)<sup>59</sup>, vastus lateralis (3cm lateral to the central point of lateral aspect of  
233 patella)<sup>59</sup>, tibialis anterior (2.5cm lateral and 5 cm inferior to the tibial tubercle)<sup>60</sup>, and thenar  
234 eminence. Participants were asked to state the moment the sensation on their skin changed from  
235 one solely of pressure to an additional “burning”, “stabbing”, “piercing” or “tearing” sensation,  
236 as described in the protocol of the DFNS. The participants were advised to indicate, by pushing a  
237 button, when the sensation on the skin changed from just pressure to pain.

238 Thermal detection and pain thresholds: thermal testing was performed with a Thermal  
239 Sensory Analyser II (Medoc, Israel).<sup>55</sup> A 3x3 cm thermode which applies warm and cold stimuli  
240 was placed over the skin and starting at 32°C, the device decreased or increased the temperature  
241 by 1°C/s. Thermal detection thresholds and pain thresholds were tested over the greater  
242 trochanter (5cm distal and 2cm anterior to greater trochanter),<sup>9</sup> and the thenar eminence. A  
243 temperature limit was set for 50°C and 0°C. For the cold and warm detection thresholds (CDT,  
244 WDT respectively), the participant was asked to press a stop button as soon as the perception of  
245 cold/warmth occurred respectively. For the cold and heat pain thresholds (CPT, HPT  
246 respectively), the participant was advised to press a button as soon as the feeling changed from  
247 just cold/heat into an additional “burning”, “stabbing”, “piercing” or “tearing” sensation, as  
248 described in the protocol of the DFNS.

249

## 250 *Statistical Analysis*

251 Descriptive statistics outlined participant symptom characteristics including their pain, hip  
252 functional, and psychosocial levels. For descriptive purposes, pain frequency and location maps

253 were created. The data distribution was initially assessed with the Shapiro-Wilk test which  
254 demonstrated a non-normal distribution. Therefore, a Mann-Whitney U test was used to assess for  
255 differences in pain extent (shown in pain drawings) between men and women and Spearman (non-  
256 linear) correlation coefficients were used to investigate the relationship between pain extent and:

257 1) Patient reported outcome measures, including measures of widespread pain  
258 and neuropathic pain (FSQ-WPI and PD-Q), hip symptoms (VAS, OHS and VKS), and  
259 psychosocial variables (PCS, TSK, CPAQ, and DASS).

260 2) QST data (PPTs and TPTs).

261 The statistical analysis was conducted using International Business Machines Statistical  
262 Package for the Social Sciences (IBM Corp, Armonk, NY, USA) version 25 and the level of  
263 significance was set at  $<0.05$ .

264

## 265 RESULTS

266 Thirty participants with hip OA (15 female) were enrolled in the study. Participant  
267 characteristics including their descriptive information (gender, age, BMI, VAS score), patient  
268 reported outcome scores, and QST data are included in Table 1. Figures 1 and 2 detail the pain  
269 frequency and location maps respectively, with dorsal and frontal views for men and women  
270 displayed separately. The mean pain extent was 6.71% (of the total body chart area) for women  
271 and 2.65% for men respectively. The Mann Whitney U test demonstrated a statistically significant  
272 difference ( $z = -2.76$ ,  $p < 0.01$ ) in mean pain extent between men and women. The pain frequency  
273 (Figure 1) and location maps (Figure 2) demonstrated that the most common site of symptoms  
274 were located around the hip joints, gluteal region and lumbar spine for both male and female

275 participants. However, several participants experienced pain beyond the immediate anatomical  
276 regions with women showing higher levels of bilateral and widespread pain than men. In  
277 particular, the male participants did not report pain anteriorly above the abdomen or down either  
278 arm. Male participants also reported cases of shoulder (4), neck (3), head (2), and distal leg  
279 symptoms compared with females. No significant correlation was found between pain extent and  
280 participant age ( $r_s = -0.1682$ ) or BMI ( $r_s = -.009$ ) (Table 2).

### 281 *Relationship between pain extent and patient reported outcome measures*

282 Pain extent scores demonstrated statistically significant positive associations with scores  
283 on the Widespread Pain Index ( $r_s = 0.426$ ,  $p < 0.05$ ), Pain Detect ( $r_s = 0.394$ ,  $p < 0.05$ ) and the pain  
284 catastrophizing Scale ( $r_s = 0.413$ ,  $p < 0.05$ ). No statistically significant associations were found  
285 between pain extent and VAS ( $r_s = 0.187$ ), FMS-SSS ( $r_s = 0.354$ ), OHS ( $r_s = 0.314$ ), VKS ( $r_s =$   
286  $0.308$ ), TSK ( $r_s = 0.172$ ), DASS-D ( $r_s = 0.316$ ), DASS-A ( $r_s = 0.312$ ) or DASS-S ( $r_s = 0.245$ ).

### 287 *Relationship between pain extent and QST data*

288 Pain extent scores were significantly associated with lower PPTs at the thenar eminence  
289 ( $r_s = -0.410$ ,  $p < 0.05$ ), vastus lateralis ( $r_s = -0.530$ ,  $p < 0.01$ ), vastus medialis ( $r_s = -0.363$ ,  $p < 0.05$ )  
290 and greater trochanter ( $r_s = -0.373$ ,  $p < 0.05$ ). Pain extent was also associated with higher CPTs at  
291 the greater trochanter ( $r_s = 0.503$ ,  $p < 0.01$ ), reduced HPTs at the greater trochanter ( $r_s = -0.382$ ,  
292  $p < 0.05$ ), and reduced WDTs over the thenar eminence ( $r_s = -0.390$ ,  $p < 0.05$ ). No significant  
293 associations were observed between pain extent and PPTs measured over the tibialis anterior ( $r_s =$   
294  $-0.354$ ) or gluteus medius ( $r_s = -0.345$ ). No significant association was measured between pain  
295 extent and HPTs ( $r_s = -0.337$ ), CPTs ( $r_s = 0.259$ ), or CDTs ( $r_s = 0.079$ ) over the thenar eminence. No

296 significant association was calculated between pain extent and WDTs ( $r_s = -0.085$ ) or CDTs ( $r_s =$   
297  $-0.134$ ) measured over the greater trochanter.

298

## 299 DISCUSSION

300 This is the first study to evaluate pain extent and relate it to symptoms of central  
301 sensitization in participants with hip OA. The use of digital pain drawings has been shown to be  
302 reliable in patients with chronic spinal pain<sup>28</sup> and was recommended to reduce errors in transferring  
303 images to a digital medium, while allowing for corrections to be made by patients prior to being  
304 uploaded.<sup>22</sup> Based on our results and similar studies<sup>22,23</sup>, digital pain drawings offer a convenient  
305 method for researchers and clinicians to quantify pain extent in patients with OA. Other studies  
306 using pain drawings on patients with hip pain have utilized participants awaiting, or having had,  
307 operative procedures with unclear<sup>33</sup> or heterogenous clinical populations.<sup>17,32,61,62</sup> Only one study  
308 has targeted patients with mild to moderate hip OA specifically<sup>22</sup>, but focused on description of  
309 symptom distribution only.

310 The pain frequency maps demonstrated that participants experienced pain beyond the hip  
311 region and immediate surrounding anatomical regions. The pain location map demonstrated that  
312 the most common areas of pain in both genders were the buttock, lumbar spine, and anterior thighs.  
313 Interestingly there were few participants who reported pain in the posterior thigh which is similar  
314 to other studies examining pain extent in patients with hip OA.<sup>22</sup> In general, women demonstrated  
315 greater pain extent bilaterally, anteriorly proximal to the abdomen, and distal to the knee. However  
316 men reported minimal symptoms in the thoracic region (especially anteriorly), arms and head or  
317 face. The descriptive detail from the pain frequency and location maps was reinforced by the pain

318 extent calculations, which demonstrated that women presented with larger pain extent compared  
319 to men. This is consistent with results from studies investigating patients with whiplash<sup>29</sup> and knee  
320 OA.<sup>23</sup> As an exclusion criteria for this study was other painful conditions, these results have  
321 potentially important clinical implications. Therefore, clinicians and researchers should be aware  
322 that patients with hip OA, especially women, often present with symptoms of widespread pain.

323 Patient reported outcomes assess components of central sensitization but currently, due to  
324 the complexity of patient presentations, the inclusion of key subjective indicators and physical  
325 examination techniques are required for diagnosis.<sup>16</sup> The Fibromyalgia Survey Questionnaire  
326 (FSQ), which was designed for a patient population with well-recognized signs and symptoms of  
327 central sensitization (i.e. fibromyalgia),<sup>63,64</sup> was chosen as an indirect measure of signs and  
328 symptoms of central sensitization for this study. While, no association was found between pain  
329 extent and the Symptom Severity Subscale, a significant association was found with the WPI.<sup>36</sup>  
330 As the WPI determines the extent and location of pain distribution it is perhaps not surprising that  
331 a significant association was found with pain extent. Increased pain extent was also significantly  
332 associated with higher PainDETECT scores. This is consistent with other studies in patients with  
333 hip<sup>9</sup> and knee OA<sup>65,66</sup> which showed that increased PainDETECT scores were associated with  
334 clinical signs of central sensitization.

335 Although this study shows significant associations between increased pain extent and these  
336 indirect measures of signs and symptoms of central sensitization, further research is required to  
337 consolidate these findings. Currently, there is a lack of consensus over the most appropriate patient  
338 reported outcome measure to assess for signs of central sensitization and therefore, the validation  
339 of an appropriate tool in patients with hip OA is a research priority.



340           Larger pain extent was associated with reduced PPTs at four of six sites (thumb, vastus  
341   lateralis, vastus medialis, and greater trochanter), three of which were remote sites. These results  
342   suggest that the participants in this study demonstrated secondary hyperalgesia, which is a key  
343   indicator of central sensitization<sup>15</sup> and is in agreement with other studies on patients with hip  
344   OA.<sup>9,67</sup> Taken collectively, these results suggest digital pain drawings could be used clinically as  
345   an appropriate screening tool for central sensitization in patients with hip OA.

346           No significant association was found between pain extent and pain intensity (measured  
347   on the VAS) or levels of function and disability (measured on the VKS or the OHS respectively)  
348   which contrasts studies conducted on patients with knee OA,<sup>23</sup> and women with fibromyalgia.<sup>26</sup>  
349   This may be associated with the mild to moderate symptoms of this studies cohort, or could  
350   suggest that the primary pain mechanism underlying hip OA is not from peripheral nociceptive  
351   input.<sup>26,68</sup> The presence of secondary hyperalgesia highlighted above has been associated with  
352   dysfunction in the descending inhibitory systems and adds further evidence to the suggestion that  
353   central changes may be present in patients with hip OA.<sup>24</sup>

354           Overall TPT testing showed inconsistent results with with three of eight sites (37.5%)  
355   demonstrating a significant correlation with pain extent. Interestingly, local thermal pain  
356   threshold (greater trochanter HPT and CPT) showed a significant correlation with pain extent  
357   while detection thresholds (greater trochanter WDT and CDT) did not. Although altered  
358   processing of thermal stimulus has been associated with both central sensitization<sup>69</sup> and small  
359   fibre dysfunction in neuropathic pain states<sup>26,28</sup>, these TPT values appeared to be within normal  
360   limits. Therefore, limited conclusions can be drawn from the TPT. TPT testing represents a gap  
361   in the evidence base that could be explored more thoroughly in future studies.

362 A significant correlation was observed between larger pain extent and the degree of pain  
363 catastrophizing, an indication of whether participants fixate on, or feel despondent about their  
364 ability to control their pain.<sup>46</sup> Apprehension to movement has been identified as a predictors for  
365 developing chronic pain,<sup>70</sup> and a previous study demonstrated differences in the Tampa Scale of  
366 Kinesiophobia (TSK) scores between patients with hip OA and controls.<sup>9</sup> However, our study  
367 found no correlation between pain extent and TSK scores, which is consistent with previous knee  
368 OA<sup>23</sup> or whiplash<sup>29</sup> studies. Furthermore, no other significant correlations were identified with  
369 the other psychosocial patient reported outcome measures (PAQ and DASS sub-scores). Carnes  
370 et al., (2006)<sup>71</sup> systematically reviewed the value of pain drawings in predicting psychosocial  
371 distress but found insufficient evidence to support this. Of 19 included studies, only 3 showed  
372 significant associations between pain drawings and levels of psychological distress and no  
373 studies included patients with hip OA.

374 Central sensitization involves the altered functioning in several overlapping components  
375 of the nervous system, including the facilitatory and inhibitory aspects of the descending neurons  
376 which moderate nociceptive input,<sup>64</sup> and increased activity in several supra-spinal centres such as  
377 the such as the anterior cingulate cortex , prefrontal cortex, and limbic system.<sup>72</sup> This  
378 neurological complexity leads to great heterogeneity in clinical symptom presentation and  
379 although a classification system has been suggested for identification of central sensitization,<sup>16</sup> it  
380 has not been validated in OA populations to date. Therefore, the underlying complexity of  
381 central sensitization may reflect the infrequent associations measured between increased pain  
382 extent and the potential presence of neuropathic pain and psychosocial distress.

383

384 *Methodological considerations*

385 To date, no data exists on pain drawing reliability in patients with hip OA. However, test-  
386 retest reliability of pain drawings has already been established for patients with spinal pain<sup>28</sup> and  
387 during provoked pain in asymptomatic subjects<sup>35</sup>, which suggests that pain drawings may well be  
388 reliable in this study too. The sample size was relatively small in this study and the participants  
389 had mild to moderate hip OA. Furthermore, there were no matched control participants in this  
390 study. Therefore, the results may not be generalizable to all patients with hip OA, especially  
391 those with more severe symptoms, and future research could determine normative TPT values  
392 both local and distant to the hip in asymptomatic participants so these results can be placed in  
393 context.

#### 394 *Conclusion*

395 Increased pain extent in people with hip OA was associated with higher scores on the  
396 Widespread Pain Index, PainDETECT, and the Pain Catastrophising Scale. Additionally, larger  
397 pain extent was associated with lower PPT measured both locally and at remote sites. Pain  
398 drawings may be useful clinically to identify increased pain extent, thereby contributing to early  
399 diagnosis of central sensitization. Future research should determine the reliability and validity of  
400 pain drawings and establish a validated patient reported outcome measure to evaluate for the  
401 presence of central sensitization in patients with hip OA.

402

#### 403 **Declaration of interest**

404 All authors declare no conflicts of interest.

#### 405 **Funding**

406 This research did not receive any specific grant from funding agencies in the public, commercial,  
407 or not-for-profit sectors.

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425 REFERENCES

- 426 1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289  
427 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study  
428 2010. *Lancet*. 2012;380:2163–2196.
- 429 2. Fernandes L, Hagen KB, Bijlsma JW, et al. EULAR recommendations for the non-pharmacological  
430 core management of hip and knee osteoarthritis. *Annals of the rheumatic diseases*.  
431 2013;72(7):1125-1135.
- 432 3. Bennell KL, Egerton T, Martin J, et al. Effect of physical therapy on pain and function in patients  
433 with hip osteoarthritis: a randomized clinical trial. *Jama*. 2014;311(19):1987-1997.
- 434 4. Arthritis Research UK (2013). Osteoarthritis in General Practice. 2013.
- 435 5. Murphy LB, Helmick CG, Schwartz TA, et al. One in four people may develop symptomatic hip  
436 osteoarthritis in his or her lifetime. *Osteoarthritis and cartilage*. 2010;18(11):1372-1379.
- 437 6. Bennell KL, Dobson F, Hinman RS. Exercise in osteoarthritis: moving from prescription to  
438 adherence. *Best practice & research. Clinical rheumatology*. 2014;28(1):93-117.
- 439 7. Hawker GA, Stewart L, French MR, et al. Understanding the pain experience in hip and knee  
440 osteoarthritis--an OARSI/OMERACT initiative. *Osteoarthritis and cartilage*. 2008;16(4):415-422.
- 441 8. Lluch E, Torres R, Nijs J, Van Oosterwijck J. Evidence for central sensitization in patients with  
442 osteoarthritis pain: a systematic literature review. *European journal of pain*. 2014;18(10):1367-  
443 1375.
- 444 9. Gwilym SE, Keltner JR, Warnaby CE, et al. Psychophysical and functional imaging evidence  
445 supporting the presence of central sensitization in a cohort of osteoarthritis patients. *Arthritis  
446 and rheumatism*. 2009;61(9):1226-1234.
- 447 10. Kosek E, Ordeberg G. Abnormalities of somatosensory perception in patients with painful  
448 osteoarthritis normalize following successful treatment. *European journal of pain*.  
449 2000;4(3):229-238.
- 450 11. Graven-Nielsen T, Arendt-Nielsen L. Assessment of mechanisms in localized and widespread  
451 musculoskeletal pain. *Nature reviews. Rheumatology*. 2010;6(10):599-606.
- 452 12. Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of  
453 musculoskeletal pain: part 1 of 3: symptoms and signs of central sensitisation in patients with  
454 low back (+/- leg) pain. *Manual therapy*. 2012;17(4):336-344.
- 455 13. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central  
456 neural plasticity. *The journal of pain : official journal of the American Pain Society*.  
457 2009;10(9):895-926.
- 458 14. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. *Pain*.  
459 2011;152(3 Suppl):S2-15.
- 460 15. Arendt-Nielsen L, Skou ST, Nielsen TA, Petersen KK. Altered Central Sensitization and Pain  
461 Modulation in the CNS in Chronic Joint Pain. *Current osteoporosis reports*. 2015;13(4):225-234.
- 462 16. Nijs J, Torres-Cueco R, van Wilgen CP, et al. Applying modern pain neuroscience in clinical  
463 practice: criteria for the classification of central sensitization pain. *Pain Physician* 2014;17:447-  
464 457.
- 465 17. Khan AM, McLoughlin E, Giannakas K, Hutchinson C. Hip osteoarthritis: where is the pain? *Ann R  
466 Coll Surg Engl* 2004;2004(86).
- 467 18. Nakamura J, Oinuma K, Ohtori S, et al. Distribution of hip pain in osteoarthritis patients  
468 secondary to developmental dysplasia of the hip. *Mod Rheumatol*. 2013;23:119-124.

- 469 19. Fingleton C, Smart K, Moloney N, Fullen BM, Doody C. Pain sensitization in people with knee  
470 osteoarthritis: a systematic review and meta-analysis. *Osteoarthritis and cartilage*.  
471 2015;23(7):1043-1056.
- 472 20. Riddle DL, Stratford PW. Knee Pain During Daily Tasks, Knee Osteoarthritis Severity, and  
473 Widespread Pain. *Physical therapy*. 2014;94(4):490-498.
- 474 21. Wood LR, Peat G, Thomas E, Duncan R. Knee osteoarthritis in community-dwelling older adults:  
475 are there characteristic patterns of pain location? *Osteoarthritis and cartilage*. 2007;15(6):615-  
476 623.
- 477 22. Poulsen E, Overgaard S, Vestergaard JT, Christensen HW, Hartvigsen J. Pain distribution in  
478 primary care patients with hip osteoarthritis. *Family practice*. 2016;33(6):601-606.
- 479 23. Lluch Girbes E, Duenas L, Barbero M, et al. Expanded Distribution of Pain as a Sign of Central  
480 Sensitization in Individuals With Symptomatic Knee Osteoarthritis. *Physical therapy*.  
481 2016;96(8):1196-1207.
- 482 24. Ferrer-Pena R, Munoz-Garcia D, Calvo-Lobo C, Fernandez-Carnero J. Pain Expansion and Severity  
483 Reflect Central Sensitization in Primary Care Patients with Greater Trochanteric Pain Syndrome.  
484 *Pain medicine*. 2018.
- 485 25. Hullemann P, Keller T, Kabelitz M, Freynhagen R, Tolle T, Baron R. Pain Drawings Improve  
486 Subgrouping of Low Back Pain Patients. *Pain practice : the official journal of World Institute of*  
487 *Pain*. 2017;17(3):293-304.
- 488 26. Barbero M, Fernandez-de-Las-Penas C, Palacios-Cena M, Cescon C, Falla D. Pain extent is  
489 associated with pain intensity but not with widespread pressure or thermal pain sensitivity in  
490 women with fibromyalgia syndrome. *Clinical rheumatology*. 2017;36(6):1427-1432.
- 491 27. Fernandez-de-Las-Penas C, Falla D, Palacios-Cena M, De-la-Llave-Rincon AI, Schneebeli A,  
492 Barbero M. Perceived Pain Extent Is Not Associated with Physical, Psychological, or  
493 Psychophysical Outcomes in Women with Carpal Tunnel Syndrome. *Pain medicine*. 2018.
- 494 28. Barbero M, Moresi F, Leoni D, Gatti R, Egloff M, Falla D. Test-retest reliability of pain extent and  
495 pain location using a novel method for pain drawing analysis. *European journal of pain*.  
496 2015;19(8):1129-1138.
- 497 29. Falla D, Peolsson A, Peterson G, et al. Perceived pain extent is associated with disability,  
498 depression and self-efficacy in individuals with whiplash-associated disorders. *European journal*  
499 *of pain*. 2016;20(9):1490-1501.
- 500 30. Fernandez-de-Las-Penas C, Falla D, Palacios-Cena M, et al. Perceived Pain Extent is Not  
501 Associated With Widespread Pressure Pain Sensitivity, Clinical Features, Related Disability,  
502 Anxiety, or Depression in Women With Episodic Migraine. *Clin J Pain*. 2018;34(3):217-221.
- 503 31. Palacios-Cena M, Barbero M, Falla D, Ghirlanda F, Arend-Nielsen L, Fernandez-de-Las-Penas C.  
504 Pain Extent Is Associated with the Emotional and Physical Burdens of Chronic Tension-Type  
505 Headache, but Not with Depression or Anxiety. *Pain medicine*. 2017;18(10):2033-2039.
- 506 32. Morimoto Y, Kondo Y, Shimosako J, et al. Investigation of Pain in Hip Disease Patients before and  
507 after Arthroplasty. *J.Phys. Ther. Sci*. 2011;23:535-538.
- 508 33. Leshner JM, Dreyfuss P, Hager N, Kaplan M, Furman M. Hip joint pain referral patterns: a  
509 descriptive study. *Pain medicine*. 2008;9(1):22-25.
- 510 34. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies  
511 in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Journal of*  
512 *clinical epidemiology*. 2008;61(4):344-349.
- 513 35. Leoni D, Falla D, Heitz C, et al. Test-retest Reliability in Reporting the Pain Induced by a Pain  
514 Provocation Test: Further Validation of a Novel Approach for Pain Drawing Acquisition and  
515 Analysis. *Pain practice : the official journal of World Institute of Pain*. 2017;17(2):176-184.

- 516 36. Hauser W, Jung E, Erbsloh-Moller B, et al. Validation of the Fibromyalgia Survey Questionnaire  
517 within a cross-sectional survey. *PLoS one*. 2012;7(5):e37504.
- 518 37. Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia criteria and severity scales for clinical and  
519 epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for  
520 Fibromyalgia. *The Journal of rheumatology*. 2011;38(6):1113-1122.
- 521 38. Freynhagen R, Tolle TR, Gockel U, Baron R. The painDETECT project - far more than a screening  
522 tool on neuropathic pain. *Current medical research and opinion*. 2016;32(6):1033-1057.
- 523 39. Moreton BJ, Tew V, das Nair R, Wheeler M, Walsh DA, Lincoln NB. Pain phenotype in patients  
524 with knee osteoarthritis: classification and measurement properties of painDETECT and self-  
525 report Leeds assessment of neuropathic symptoms and signs scale in a cross-sectional study.  
526 *Arthritis care & research*. 2015;67(4):519-528.
- 527 40. Naal FD, Sieverding M, Impellizzeri FM, von Knoch F, Mannion AF, Leunig M. Reliability and  
528 validity of the cross-culturally adapted German Oxford hip score. *Clinical orthopaedics and  
529 related research*. 2009;467(4):952-957.
- 530 41. Klasen BW, Hallner D, Schaub C, Willburger R, Hasenbring M. Validation and reliability of the  
531 German version of the Chronic Pain Grade questionnaire in primary care back pain patients.  
532 *GMS Psycho-Social-Medicine*. 2004;1:Doc07 (20041014).
- 533 42. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. *Pain*.  
534 1992;50(2):133-149.
- 535 43. Hjerstad MJ, Fayers PM, Haugen DF, et al. Studies comparing Numerical Rating Scales, Verbal  
536 Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic  
537 literature review. *Journal of pain and symptom management*. 2011;41(6):1073-1093.
- 538 44. Alghadir AH, Anwer S, Iqbal A, Iqbal ZA. Test-retest reliability, validity, and minimum detectable  
539 change of visual analog, numerical rating, and verbal rating scales for measurement of  
540 osteoarthritic knee pain. *Journal of pain research*. 2018;11:851-856.
- 541 45. Meyer K, Sprott H, Mannion AF. Cross-cultural adaptation, reliability, and validity of the German  
542 version of the Pain Catastrophizing Scale. *Journal of psychosomatic research*. 2008;64(5):469-  
543 478.
- 544 46. Sullivan MJL, Bishop SR. Pain Catastrophizing Scale: development and validation. *Psychological  
545 Assessment*. 1995;7:524-532.
- 546 47. Keefe FJ, Lefebvre JC, Egert JR, Affleck G, Sullivan MJ, Caldwell DS. The relationship of gender to  
547 pain, pain behaviour, and disability in osteoarthritis patients: the role of catastrophizing *Pain*.  
548 2000;87:325-334.
- 549 48. Rusu AC, Kreddig N, Hallner D, Hulsebusch J, Hasenbring MI. Fear of movement/(Re)injury in low  
550 back pain: confirmatory validation of a German version of the Tampa Scale for Kinesiophobia.  
551 *BMC musculoskeletal disorders*. 2014;15:280.
- 552 49. Vlaeyen JWS, Kole-Snijders AMK, Boeren RGB, Van Eek H. Fear of movement/( re) injury in  
553 chronic low back pain and its relation to behavioral performance. *Pain*. 1995;62 (3):363-372.
- 554 50. Vlaeyen JWS, Kole-Snijders AMJ, Rotteveel A, Ruesink R, Heuts PHTG. The role of fear of  
555 movement/ (re)injury in pain disability *J Occup Rehab*. 1995;5(4):235-252.
- 556 51. McCracken LM, Vowles KE, Eccleston C. Acceptance-based treatment for persons with complex,  
557 long standing chronic pain: a preliminary analysis of treatment outcome in comparison to a  
558 waiting phase. *Behaviour research and therapy*. 2005;43(10):1335-1346.
- 559 52. McCracken LM, Vowles KE, Eccleston C. Acceptance of chronic pain: component analysis and a  
560 revised assessment method. *Pain*. 2004;107(1):159-166.
- 561 53. Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-  
562 21): construct validity and normative data in a large non-clinical sample. *The British journal of  
563 clinical psychology*. 2005;44(Pt 2):227-239.

- 564 54. Nilges P, Essau C. [Depression, anxiety and stress scales: DASS--A screening procedure not only  
565 for pain patients]. *Schmerz*. 2015;29(6):649-657.
- 566 55. Rolke R, Baron R, Maier C, et al. Quantitative sensory testing in the German Research Network  
567 on Neuropathic Pain (DFNS): standardized protocol and reference values. *Pain*. 2006;123(3):231-  
568 243.
- 569 56. Lluch E, Arguisuelas MD, Coloma PS, Palma F, Rey A, Falla D. Effects of deep cervical flexor  
570 training on pressure pain thresholds over myofascial trigger points in patients with chronic neck  
571 pain. *Journal of manipulative and physiological therapeutics*. 2013;36(9):604-611.
- 572 57. Fernandez-de-las-Penas C, Perez-de-Heredia M, Brea-Rivero M, Miangolarra-Page JC. Immediate  
573 effects on pressure pain threshold following a single cervical spine manipulation in healthy  
574 subjects. *The Journal of orthopaedic and sports physical therapy*. 2007;37(6):325-329.
- 575 58. Izumi M, Petersen KK, Laursen MB, Arendt-Nielsen L, Graven-Nielsen T. Facilitated temporal  
576 summation of pain correlates with clinical pain intensity after hip arthroplasty. *Pain*.  
577 2017;158(2):323-332.
- 578 59. Arendt-Nielsen L, Nie H, Laursen MB, et al. Sensitization in patients with painful knee  
579 osteoarthritis. *Pain*. 2010;149(3):573-581.
- 580 60. Walton DM, Macdermid JC, Nielson W, Teasell RW, Chiasson M, Brown L. Reliability, Standard  
581 Error, and Minimum Detectable Change of Clinical Pressure Pain Threshold Testing in People  
582 With and Without Acute Neck Pain. *The Journal of orthopaedic and sports physical therapy*.  
583 2011;41(9):644-650.
- 584 61. Sakamoto J, Morimoto Y, Ishii S, et al. Investigation and Macroscopic Anatomical Study of  
585 Referred Pain in Patients with Hip Disease. *J. Phys. Ther. Sci*. 2014;26:203–208.
- 586 62. Hsieh PH, Chang Y, Chen DW, Lee MS, Shih HN, Ueng SW. Pain distribution and response to total  
587 hip arthroplasty: a prospective observational study in 113 patients with end-stage hip disease.  
588 *Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association*.  
589 2012;17(3):213-218.
- 590 63. Desmeules JA, Cedraschi C, Rapiti E, et al. Neurophysiologic evidence for a central sensitization  
591 in patients with fibromyalgia. *Arthritis and rheumatism*. 2003;48(5):1420-1429.
- 592 64. Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic widespread  
593 pain in patients with fibromyalgia and chronic fatigue syndrome. *Clinical rheumatology*.  
594 2007;26(4):465-473.
- 595 65. Hochman JR, Gagliese L, Davis AM, Hawker GA. Neuropathic pain symptoms in a community  
596 knee OA cohort. *Osteoarthritis and cartilage*. 2011;19(6):647-654.
- 597 66. Hochman JR, Davis AM, Elkayam J, Gagliese L, Hawker GA. Neuropathic pain symptoms on the  
598 modified painDETECT correlate with signs of central sensitization in knee osteoarthritis.  
599 *Osteoarthritis and cartilage*. 2013;21(9):1236-1242.
- 600 67. Suokas AK, Walsh DA, McWilliams DF, et al. Quantitative sensory testing in painful  
601 osteoarthritis: a systematic review and meta-analysis. *Osteoarthritis and cartilage*.  
602 2012;20(10):1075-1085.
- 603 68. Staud R, Price DD, Robinson ME, Vierck CJ, Jr. Body pain area and pain-related negative affect  
604 predict clinical pain intensity in patients with fibromyalgia. *The journal of pain : official journal of*  
605 *the American Pain Society*. 2004;5(6):338-343.
- 606 69. Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely RH. Increased pain sensitivity in fibromyalgia:  
607 effects of stimulus type and mode of presentation. *Pain*. 2003;105(3):403-413.
- 608 70. Leeuw M, Goossens ME, Linton SJ, Crombez G, Boersma K, Vlaeyen JW. The fear-avoidance  
609 model of musculoskeletal pain: current state of scientific evidence. *Journal of behavioral*  
610 *medicine*. 2007;30(1):77-94.



- 611 71. Carnes D, Ashby D, Underwood M. A systematic review of pain drawing literature: should pain  
612 drawings be used for psychologic screening? . *Clin J Pain*. 2006;22(5):449-457.  
613 72. Apkarian AV, Hashmi JA, Baliki MN. Pain and the brain: Specificity and plasticity of the brain in  
614 clinical chronic pain. *Pain medicine*. 2011;152(3 Suppl):S49–S64.

615

616

617

618

619

620

621

622

623

624

## 625 FIGURE LEGENDS

626

627 Figure 1: Pain frequency maps generated by superimposing the pain drawings of all participants  
628 included in the study. Pain frequency maps have been generated separately for men and women  
629 and include the dorsal and ventral view. The color grid indicates both the number and the  
630 percentage of individuals that reported pain in that specific area. Darker colors represents the  
631 most frequently reported area of pain.

632

633 Figure 2: Pain location analysis which shows the number of individuals reporting pain in a  
634 specific body region. Darker colors represent a higher number of people reporting pain in a  
635 specific body region.

636